Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC)
ConclusionsPreventing disease progression for patients with NSCLC could reduce the economic burden of NSCLC on patients, caregivers and healthcare systems. This review provides a comprehensive overview of the available cost and resource use data in this indication, which is important in guiding the decisions of policy makers regarding the allocation of resources. However, it also indicates a need for more studies comparing the economic impact of NSCLC in markets in addition to the US. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 30, 2023 Category: Health Management Source Type: research
Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia
ConclusionsSurvival improvements for advanced lung cancer have been accompanied by growing treatment costs. The estimates reported here can be used for budget planning and economic evaluations of interventions across the spectrum of cancer control. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 25, 2023 Category: Health Management Source Type: research
Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review
ConclusionLBs could provide a cost-effective approach for treatment selection in lung cancer and aid in the screening and early detection of other cancers, including colorectal, gastric, breast, and brain cancers. This is in comparison with various alternatives, such as the standard of care (SOC) and no screening scenario. However, it is important to mention that in some comparisons, LBs were used in combination with SOC instead of replacing it. Importantly, few studies have pointed toward LBs ’ cost-effectiveness for monitoring treatment response. Most health and budget impact analyses, especially those focused on lung ...
Source: PharmacoEconomics - June 23, 2023 Category: Health Management Source Type: research
EQ-5D-5L Value Set for Slovenia
ConclusionsResults have important implications for users of the EQ-5D-5L in Slovenia and regions. It is a robust and up-to-date value set and should be the preferred value set used in adults in Slovenia and in neighbouring countries without their own value set. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 21, 2023 Category: Health Management Source Type: research
Jumping the Queue:Willingness to Pay for Faster Access to COVID-19 Vaccines in Seven European Countries
ConclusionWe find that most respondents would have been willing to pay for faster access to COVID vaccines (jumping the queue), suggesting welfare gains from quicker access to these vaccines. This is an important result in light of potential future outbreaks and vaccines. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 21, 2023 Category: Health Management Source Type: research
Modelling the Cost Effectiveness of Treatments for Parkinson ’s Disease: An Updated Methodological Review
ConclusionsThe quality of economic evaluation models in Parkinson ’s disease has improved in terms of calculating cost and transition parameters, as well as carrying out probabilistic sensitivity analyses, compared with the published literature of previous systematic reviews up to 2010. However, there is still potential for further development in terms of the in tegration of non-motor complications and treatment changes, the transparent presentation of parameter estimates, as well as conducting sensitivity analyses and validations to support the interpretation of results. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 21, 2023 Category: Health Management Source Type: research
Jumping the Queue:Willingness to Pay for Faster Access to COVID-19 Vaccines in Seven European Countries
ConclusionWe find that most respondents would have been willing to pay for faster access to COVID vaccines (jumping the queue), suggesting welfare gains from quicker access to these vaccines. This is an important result in light of potential future outbreaks and vaccines. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 21, 2023 Category: Health Management Source Type: research
Modelling the Cost Effectiveness of Treatments for Parkinson ’s Disease: An Updated Methodological Review
ConclusionsThe quality of economic evaluation models in Parkinson ’s disease has improved in terms of calculating cost and transition parameters, as well as carrying out probabilistic sensitivity analyses, compared with the published literature of previous systematic reviews up to 2010. However, there is still potential for further development in terms of the in tegration of non-motor complications and treatment changes, the transparent presentation of parameter estimates, as well as conducting sensitivity analyses and validations to support the interpretation of results. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 21, 2023 Category: Health Management Source Type: research
EQ-5D-5L Value Set for Slovenia
ConclusionsResults have important implications for users of the EQ-5D-5L in Slovenia and regions. It is a robust and up-to-date value set and should be the preferred value set used in adults in Slovenia and in neighbouring countries without their own value set. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 21, 2023 Category: Health Management Source Type: research
Informal Caregiving Provision for Disabled or Elderly in the Families and Work Productivity: Evidence from 11 Waves of an Australian Population-Based Cohort
ConclusionOur study reveals that working-age caregivers experience greater absenteeism, presenteeism and working hour tension. Adverse effects of informal caregiving are required to perform the cost effectiveness of an intervention given to caregivers to improve carer and patient health. Our findings will assist health technology assessment (HTA) practitioners in performing an economic evaluation of interventions given to caregivers by providing the indirect cost (productivity loss) of caregiving. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 20, 2023 Category: Health Management Source Type: research
Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA
ConclusionsThis study provides comprehensive catalogues of UK/US EQ-5D-3L HRQoL utilities. Results are relevant in cost-effectiveness analysis, for NICE submissions, and for comparing and identifying facets of disease burden. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 18, 2023 Category: Health Management Source Type: research
Context-Specific Estimation of Future Unrelated Medical Costs and Their Impact on Cost-Effectiveness Analyses
ConclusionOur case study revealed that the inclusion of UFMC had modest effect on the ICERs, and thus did not alter the conclusion. Thus, we should estimate context-specific UFMC if they are expected to change the ICERs significantly, and transparently report the corresponding assumptions to uphold the integrity and reliability of the economic evaluation. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 17, 2023 Category: Health Management Source Type: research
